Literature DB >> 1706917

Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour.

F Markwardt1, M Richter, P Walsmann, G Riesener, M Paintz.   

Abstract

Recombinant desulphatohirudin was bound via lysine residues to oxidized dextrans. The hirudin-dextran conjugates inhibit thrombin like free hirudin. The Ki-values are in the same range. In rabbits and rats the pharmacokinetic behaviour following i.v. administration of these conjugates was examined in comparison to that of hirudin. The hirudin-dextran conjugates were more slowly eliminated than hirudin, the distribution volumes in steady-state were significantly reduced, and, in comparison to hirudin, 5 to 15 times larger areas under the plasma concentration-time-curves were obtained.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706917

Source DB:  PubMed          Journal:  Biomed Biochim Acta        ISSN: 0232-766X


  3 in total

1.  The stabilization and release of hirudin from liposomes or lipid-assemblies coated with hydrophobically modified dextran.

Authors:  R J Mumper; A S Hoffman
Journal:  AAPS PharmSciTech       Date:  2000-03-03       Impact factor: 3.246

Review 2.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

3.  A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity.

Authors:  Zhuguo Liu; Zheng Yu; Yuanyuan Huang; Yan Zhang; Guozhu Han; Xian Li; Mingxin Dong; Shuo Yu; Yu Wang; Jie Hu; Huiqin Guo; Yuanguo Cheng; Li Lv; Qiuyun Dai
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.